# Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence

> **NCT01526837** · PHASE1 · TERMINATED · sponsor: **Brain & Spine Surgeons of New York** · enrollment: 1 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Avastin

## Key facts

- **NCT ID:** NCT01526837
- **Lead sponsor:** Brain & Spine Surgeons of New York
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Investigators decision
- **Last updated:** 2017-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01526837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01526837, "Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01526837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*